Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment

Molecular Therapy

Volumn 4, Issue 1, 2001, Pages 5-12

  Atencio, Isabella A ^a   Avanzini, Jenny B ^a   Johnson, Duane ^a   Neuteboom, Saskia ^b   Vaillancourt, Mei Ting ^a   Nielsen, Loretta L ^a   Hajian, Gerry ^a   Sutjipto, Suganto ^a   Sugarman, Barry J ^a   Philopena, Jennifer ^a   McAllister, Diane L ^a   Beltran, Josefina C ^a   Nodelman, Margarita ^a   Ramachandra, Murali ^a   Wills, Ken N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NewBiotics Inc   (United States)

Author keywords

Adenovirus; Antitumor; Apoptosis; Chemotherapeutics; Efficacy; Gene therapy; MDM2; P53; Variant

Indexed keywords

AMINO ACID; ANNEXIN; ANTINEOPLASTIC AGENT; FLUORESCEIN ISOTHIOCYANATE; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE DELETION; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN BINDING; PROTEIN VARIANT; TUMOR CELL LINE; TUMOR RESISTANCE; VIRUS RECOMBINANT;

ADENOVIRIDAE;

EID: 0034928440     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0416     Document Type: Article

References (45)

1. The role of the p53 protein in the apoptotic response
2. p53 and apoptosis
3. p53: Emergency brake and target for cancer therapy
4. TP53 tumour suppressor gene: Clues to molecular carcinogenesis and cancer therapy
5. Regulation of p53 downstream genes
6. Clinical implications of p53: Effect on prognosis, tumor progression and chemotherapy response
7. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
8. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
9. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells
10. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
11. Cancer therapy and p53
12. Gene therapy: A molecular approach to cancer treatment
13. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
14. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection
15. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors
16. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
17. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
18. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo
19. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
20. Regulation of p53 stability by Mdm2
21. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
22. Mdm2 inhibits the apoptotic function of p53 mainly by targeting It for degradation
23. In vivo ubiquitination and proteasome-mediated degradation of p53(1)
24. Effect of proteasome inhibitors on monocytic IκB-α and -β depletion, NF-κB activation, and cytokine production
25. Amplification and overexpression of mdm2 gene in ependymonas
26. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status
27. MDM2 in breast cancer
28. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)
29. Overexpression of the MDM2 oncogene in leukemia and lymphoma
30. Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells
31. The MDM2 gene amplification database
32. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2
33. Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2
34. A modified p53 overcomes mdm2-mediated oncogenic transformation: A potential cancer therapeutic agent
35. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
36. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53
37. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis
38. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles
39. The p53 tumor suppressor gene: From molecular biology to clinical investigation
40. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
41. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
42. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer
43. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography
44. Early detection of apoptosis using a fluorescent conjugate of annexin V
45. An example of using mixed models and PROC MIXED for longitudinal data